In July 2025, researchers published results in the New England Journal of Medicine that read like science fiction. Children born profoundly deaf received a single injection into one ear, and within weeks, some could hear speech for the first time. Three out of twelve patients achieved normalized hearing sensitivity, and nearly all showed clinically meaningful improvements. The therapy is called DB-OTO, developed by Regeneron Pharmaceuticals, and it targets a single missing protein that was keeping perfectly functional ears silent.
The children in the trial all carry mutations in the OTOF gene, which encodes a protein called otoferlin. This protein has one critical job: enabling the inner hair cells of the cochlea to transmit sound signals to the auditory nerve. Without it, the hair cells can detect vibrations but can’t communicate what they’re sensing — the hardware works, but the signal never gets sent. This made it an ideal gene therapy target because nothing needs to be rebuilt. You just deliver the missing instructions. The engineering challenge was that the OTOF gene is too large to fit inside a single adeno-associated virus (AAV) vector. Regeneron’s solution was to split the gene across two separate AAV particles, inject both into the cochlea, and let the halves recombine inside the same cell to produce full-length otoferlin.
A separate UC Irvine study confirmed that gene therapy for hereditary deafness is safe and effective in both children and adults, though children have a significant advantage. The brain has a critical period for auditory development in the first few years of life — treating children early gives them the best chance of normal speech and language development. Adults still benefit meaningfully, but rewiring an auditory cortex that’s been quiet for years is harder. OTOF mutations account for roughly 2 to 8 percent of hereditary hearing loss, translating to tens of thousands of potential candidates worldwide.
But OTOF is just one of over 150 genes linked to hereditary hearing loss. It’s the proof of concept: if you can split an oversized gene, deliver it to precise cells in the inner ear, and restore hearing in a child who has never heard sound, the door is open for every other gene on the list. Five years ago, restoring hearing in a congenitally deaf child was theoretical. Today it’s published in the New England Journal of Medicine. This is the first chapter, not the whole book.
In July 2025, researchers published results from a clinical trial that read like science fiction. Children born profoundly deaf received a single injection into one ear. Within weeks, some of them could hear speech for the first time in their lives. The therapy is called DB-OTO, and the results published in the New England Journal of Medicine showed that 3 out of 12 patients achieved normalized hearing sensitivity. From silence to sound, with one injection.
Nearly all 12 children showed clinically meaningful hearing improvements. The three who achieved normalized sensitivity were the standout results, but the broader group demonstrated significant gains in their ability to detect and respond to sound. A press release from Regeneron Pharmaceuticals, which developed the therapy, described the results as demonstrating “clinically meaningful hearing improvements in nearly all children.”
The children in this trial all had the same genetic condition. They carry mutations in a gene called OTOF, which encodes a protein called otoferlin. Otoferlin is essential for one very specific job: it enables the inner hair cells in your cochlea to transmit sound signals to the auditory nerve. Without functioning otoferlin, those hair cells can detect vibrations but cannot communicate what they’re detecting. The machinery works, but the signal never gets sent.
That’s the key distinction. In most forms of hearing loss, the hair cells themselves are damaged or destroyed. Once they’re gone, they don’t regenerate in humans. But in OTOF-related deafness, the hardware is fine. It’s a software problem. One missing protein prevents the entire chain from functioning. That makes it an ideal target for gene therapy because you don’t need to rebuild structures. You just need to deliver the missing instructions.
The therapy uses an adeno-associated virus, or AAV, as a delivery vehicle. AAVs are viruses that have been engineered to be harmless. They can’t replicate, and they’ve been used in gene therapy for decades with a strong safety record. The challenge with OTOF is that the gene is too large to fit inside a single AAV particle. It’s one of the largest genes targeted by gene therapy.
And it worked. The dual vectors are injected directly into the cochlea during a surgical procedure under general anesthesia. The AAV particles infect the inner hair cells, deliver their genetic cargo, and the cells begin producing functional otoferlin. Once the protein is present, the synaptic transmission from hair cells to auditory nerve starts working.
The results showed improvements within weeks. A July 2025 report from ScienceDaily described “dramatic results just one month after a single injection.” The children went from having no measurable hearing to responding to conversational-level sounds. For the three patients with the best outcomes, hearing sensitivity approached the normal range within months.
The clinical descriptions are measured and scientific, but behind every data point is a child hearing their parent’s voice for the first time. Hearing music. Hearing their own name spoken aloud. These are children who were born into silence and are entering the world of sound at age two, three, four years old.
A separate study published by UC Irvine’s School of Medicine in July 2025 expanded the findings to include adults. Their results showed that gene therapy for hereditary deafness is “safe and effective in both children and adults.” The adult patients had lived with hearing loss for much longer, and while the improvements were meaningful, the developing brain’s plasticity gives children a significant advantage in learning to process sound after restoration.
That makes sense. A child’s brain is still wiring up for language. An adult’s auditory cortex has been quiet for years.
Precisely. There’s a concept in neuroscience called the critical period for auditory development. The brain is most receptive to organizing sound processing in the first few years of life. Treating children early maximizes the chance that restored hearing translates into normal speech and language development. Adults can still benefit significantly, but the neural rewiring is more challenging.
Over 150 genes have been linked to hereditary hearing loss. OTOF is just the first one being successfully targeted with gene therapy. The NIDCD, the National Institute on Deafness and Communication Disorders, describes gene therapy clinical trials as underway for OTOF-related deafness specifically, with research expanding toward other genetic causes.
The dual-vector approach that Regeneron pioneered could potentially be adapted for other large genes involved in hearing. And for smaller genes, single-vector therapies could be even simpler to deliver. This is likely the first chapter, not the whole book.
The Phase 1/2 CHORD trial was specifically designed to evaluate safety alongside efficacy. The AAV vectors used have a decades-long track record in other gene therapies. The surgical injection procedure carries the typical risks of cochlear surgery, including a small risk of balance disturbance. But the UC Irvine study specifically concluded that the approach is “safe” in both children and adults, with no serious adverse events reported that were attributed to the gene therapy itself.
DB-OTO is still in clinical trials. Regeneron would need to complete Phase 3 trials with larger patient groups, demonstrate consistent results, and receive regulatory approval. That process typically takes several years. But the Phase 1/2 results are strong enough that there’s genuine optimism in the field.
A child born deaf. A single injection. Sound within weeks. Three out of twelve hearing normally. And this is just the first gene, the first approach, the first generation of the technology.
- New England Journal of Medicine - “DB-OTO Gene Therapy for Inherited Deafness” - https://www.nejm.org/doi/full/10.1056/NEJMoa2400521
- Regeneron Pharmaceuticals - “Latest DB-OTO Results from CHORD Trial” - https://investor.regeneron.com/news-releases/news-release-details/latest-db-oto-results-demonstrate-clinically-meaningful-hearing/
- ScienceDaily - “Deafness reversed: Single injection brings hearing back within weeks” (2025) - https://www.sciencedaily.com/releases/2025/07/250702214148.htm
- UC Irvine School of Medicine - “Advancing Gene Therapy to Address Deafness” (2025) - https://medschool.uci.edu/news/advancing-gene-therapy-address-deafness
- NIDCD - “The Future of Gene Therapy for Hearing Loss” - https://www.nidcd.nih.gov/health/future-gene-therapy-hearing-loss
- ClinicalTrials.gov - CHORD Trial for DB-OTO
The therapy delivers a working copy of the missing gene directly into the cochlea using engineered viruses. The hair cells in the ear were intact the whole time. They just couldn’t send signals without a protein called otoferlin. Give them the gene, they make the protein, and the silence ends.
Frequently Asked Questions
Can gene therapy cure deafness?
Gene therapy has shown remarkable results for specific types of hereditary deafness. DB-OTO, targeting OTOF gene mutations, has restored hearing in children born profoundly deaf. However, it currently only works for OTOF-related deafness (~2-8% of hereditary cases). Over 150 genes are associated with hearing loss, each requiring its own therapy.
How does DB-OTO gene therapy work?
DB-OTO delivers a working copy of the OTOF gene using two AAV (adeno-associated virus) vectors injected directly into the cochlea. The OTOF gene is too large for a single AAV, so it’s split across two vectors that recombine inside the cell to produce otoferlin — the missing protein needed for hair cells to transmit sound signals.
Can adults benefit from hearing loss gene therapy?
Adults can benefit, but children respond better because the brain has a critical period for auditory development in the first few years. Adults who’ve been deaf for years face the additional challenge of rewiring an auditory cortex that hasn’t processed sound, though meaningful improvements have still been documented.
Related Episodes
If you enjoyed this episode, check out these related deep dives:
- [CRISPR Just Cured a Baby With a Drug Made Only For Him](/blog/e55-crispr-gene-editing-revolution)
- Scientists Just Grew a Human Spinal Cord in a Lab
- Cancer Breakthroughs 2025: Cracking the Undruggable